Trial Profile
An Open-label, Randomized, Comparative, Parallel Group Study to Assess the Immunogenicity of Lupin's Peg-filgrastim Versus Neulasta as an Adjunct to Chemotherapy in Patients With Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jun 2021
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Pharmacodynamics
- Sponsors Lupin
- 04 Oct 2019 Status changed from recruiting to completed.
- 30 Apr 2018 New trial record